The return journey is part of the procedure.

What guidance establishes

Coordination is clinical infrastructure.

CDC and professional guidance emphasise review of professional credentials and the treating facility, prearranged follow-up, complete medical records, insurance and financial planning for complications, and careful consideration of return-travel timing.

The return plan should identify who reviews the patient before departure, who provides routine care at home, which clinician is available for urgent review and which hospital can accept escalation. Records should be usable across languages and systems.

Transparency RegisterTR 07 · TR 06

Specialist interpretation

A handover should be designed, not assumed.

Travel changes the treatment system by separating the patient from the original team. That separation should be mapped before the procedure, including the practical limits of remote review and the authority of local clinicians.

Accreditation and credentials are relevant but cannot guarantee an outcome. The quality of the handover, access to records and the ability to escalate remain independent questions.

• Schedule postoperative review and home-country follow-up in advance.
• Transfer operative, implant, anaesthesia, medication and microbiology records.
• Clarify insurance exclusions, complication costs and medical evacuation.
• Individualise travel timing and thrombosis prevention.

Transparency RegisterTR 07 · TR 06

Evidence boundary

Public-health reports identify signals, not universal rates.

Recent CDC investigations illustrate geographically dispersed infections and severe adverse events after travel-related cosmetic procedures. Their convenience samples and location-specific data cannot estimate the overall incidence of complications or justify a generalised claim that all international surgery is unsafe.

Transparency RegisterTR 07 · TR 06